Nobuhisa Ishikawa

6.9k total citations
126 papers, 5.1k citations indexed

About

Nobuhisa Ishikawa is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Nobuhisa Ishikawa has authored 126 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Nobuhisa Ishikawa's work include Lung Cancer Treatments and Mutations (37 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (25 papers) and Lung Cancer Research Studies (17 papers). Nobuhisa Ishikawa is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (25 papers) and Lung Cancer Research Studies (17 papers). Nobuhisa Ishikawa collaborates with scholars based in Japan, Finland and Germany. Nobuhisa Ishikawa's co-authors include Nobuoki Kohno, Noboru Hattori, Yataro Daigo, Eiju Tsuchiya, Akihito Yokoyama, Tatsuya Kato, Atsushi Takano, Tomoo Ito, Kouki Inai and Satoshi Hayama and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Nobuhisa Ishikawa

119 papers receiving 5.0k citations

Peers

Countries citing papers authored by Nobuhisa Ishikawa

Since Specialization

Citations

This map shows the geographic impact of Nobuhisa Ishikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuhisa Ishikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuhisa Ishikawa more than expected).

Fields of papers citing papers by Nobuhisa Ishikawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nobuhisa Ishikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuhisa Ishikawa. The network helps show where Nobuhisa Ishikawa may publish in the future.

Co-authorship network of co-authors of Nobuhisa Ishikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Nobuhisa Ishikawa. A scholar is included among the top collaborators of Nobuhisa Ishikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobuhisa Ishikawa. Nobuhisa Ishikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Arterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising‐ VTE / NEJ037 Study 2025 ·Cancer Medicine ·Naoki Furuya, (unknown), T Hotta, Toshihide Yokoyama, Masahiro Yamasaki, Nobuhisa Ishikawa, Kazunori Fujitaka, Tetsuya Kubota, Kunihiko Kobayashi, Takeshi Isobe	1
2	Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study 2025 ·International Journal of COPD ·Kazuhiro Yatera, Zhang Wang, Yoko Shibata, Nobuhisa Ishikawa, Tetsuya Homma, Kiyoyasu Fukushima, Osamu Hataji, Yoshikazu Inoue, (unknown), Keisuke Miki, Kazuhiro Sato, Kazunori Tobino, Makoto Yoshida, Takeo Ishii, (unknown), (unknown), (unknown), Chris Compton, Paul Jones	0
3	Efficacy of immune checkpoint inhibitors according to programmed cell death‐ligand 1 expression in patients with non‐small cell lung cancer and brain metastasis: A real‐world prospective observational study 2024 ·Thoracic Cancer ·Takeshi Masuda, (unknown), K. Hata, (unknown), Katsuyuki Kiura, Nobuhiro Kanaji, Takuya Inoue, Masahiro Kodani, Masaaki Yanai, Kakuhiro Yamaguchi, (unknown), Masahiro Yamasaki, Nobuhisa Ishikawa, Ken Masuda, (unknown), Shoichi Kuyama, Tetsuya Kubota, Kazuya Nishii, Katsuyuki Hotta, Noboru Hattori	2
4	Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status 2024 ·Respiratory Investigation ·Kazuhisa Nakashima, (unknown), Haruyasu Murakami, Toshiaki Takahashi, (unknown), Takashi Yanagawa, (unknown), (unknown), Masaaki Abe, Kosuke Hamai, (unknown), Nobuhisa Ishikawa, Tomoki Tamura, Shoichi Kuyama, Takeshi Isobe, Yukari Tsubata	0
5	A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer 2024 ·Cancer Control ·Kosuke Hamai, (unknown), (unknown), (unknown), (unknown), (unknown), Sayaka Ueno, (unknown), Nobuhisa Ishikawa	0
6	Burden of respiratory syncytial virus, human metapneumovirus and influenza virus infections in Japanese adults in the Hospitalized Acute Respiratory Tract Infection study 2024 ·Respiratory Investigation ·Masaharu Shinkai, Shinichiro Ota, Nobuhisa Ishikawa, (unknown), (unknown), Shuichi Abe, Yannick Vandendijck, Yoshikazu Nakayama, Yoko Murata	7
7	Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005) 2024 ·Lung ·Nobuhiro Kanaji, Eiki Ichihara, Takaaki Tanaka, Takashi Ninomiya, Toshiyuki Kozuki, Nobuhisa Ishikawa, Kazuya Nishii, (unknown), Kakuhiro Yamaguchi, (unknown), Yuko Toyoda, Masaaki Inoue, Nobuyuki Miyatake, Naoki Watanabe, Takuya Inoue, (unknown), (unknown), (unknown), Norimitsu Kadowaki	5
8	Comprehensive genomic profiling of Japanese patients with thoracic malignancies: A single-center retrospective study 2023 ·Respiratory Investigation ·(unknown), (unknown), Kosuke Hamai, (unknown), (unknown), (unknown), Sayaka Ueno, Ken Masuda, (unknown), Takashi Nishisaka, Takao Hinoi, Akira Hirasawa, Nobuhisa Ishikawa	3
9	Pseudomesotheliomatous Carcinoma of the Lung with Morphological Characteristics of Signet Ring Cell Carcinoma: An Autopsy Case Report 2023 ·Internal Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sayaka Ueno, Ken Masuda, Takashi Nishisaka, Nobuhisa Ishikawa	0
10	Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis 2014 ·Respiratory Medicine ·Shinichiro Ohshimo, Nobuhisa Ishikawa, Yasushi Horimasu, Noboru Hattori, Nobuyuki Hirohashi, Koichi Tanigawa, Nobuoki Kohno, Francesco Bonella, Josune Guzman, Ulrich Costabel	150
11	SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis 2013 ·Molecular Cancer Therapeutics ·Takeshi Masuda, Noboru Hattori, Tadashi Senoo, (unknown), Nobuhisa Ishikawa, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Nobuoki Kohno	42
12	Sputum biomarkers of inflammation in smokers and subjects with COPD 2013 ·European Respiratory Journal ·Jing Gao, (unknown), (unknown), Steffen Ohlmeier, Nobuhisa Ishikawa, Hideo Kobayashi, Tuula Toljamo, Vuokko L. Kinnula, Ville Pulkkinen, Witold Mazur	1
13	MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis 2013 ·European Respiratory Journal ·Shinichiro Ohshimo, Nobuhisa Ishikawa, Yasushi Horimasu, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Nobuyuki Hirohashi, Noboru Hattori, Koichi Tanigawa, Nobuoki Kohno, Francesco Bonella, Josune Guzman, Ulrich Costabel	2
14	Identification of Epstein-Barr Virus–Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer 2011 ·Clinical Cancer Research ·Ryohei Nishino, Atsushi Takano, (unknown), Nobuhisa Ishikawa, Hirohiko Akiyama, Hiroyuki Ito, Haruhiko Nakayama, Yohei Miyagi, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, Yataro Daigo	65
15	Wnt Inhibitor Dickkopf-1 as a Target for Passive Cancer Immunotherapy 2010 ·Cancer Research ·Nagato Sato, Takumi Yamabuki, Atsushi Takano, Junkichi Koinuma, Masato Aragaki, Ken Masuda, Nobuhisa Ishikawa, Nobuoki Kohno, Hiroyuki Ito, Masaki Miyamoto, Haruhiko Nakayama, Yohei Miyagi, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, Yataro Daigo	129
16	Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer 2009 ·Cancer Research ·Atsushi Takano, Nobuhisa Ishikawa, Ryohei Nishino, Ken Masuda, Wataru Yasui, Kouki Inai, Hitoshi Nishimura, Hiroyuki Ito, Haruhiko Nakayama, Yohei Miyagi, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, Yataro Daigo	211
17	Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer 2007 ·Clinical Cancer Research ·Masaya Taniwaki, Atsushi Takano, Nobuhisa Ishikawa, Wataru Yasui, Kouki Inai, Hitoshi Nishimura, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, Yataro Daigo	125
18	Cancer-Testis Antigen Lymphocyte Antigen 6 Complex Locus K Is a Serologic Biomarker and a Therapeutic Target for Lung and Esophageal Carcinomas 2007 ·Cancer Research ·Nobuhisa Ishikawa, Atsushi Takano, Wataru Yasui, Kouki Inai, Hitoshi Nishimura, Hiroyuki Ito, Yohei Miyagi, Haruhiko Nakayama, Masahiro Fujita, Masao Hosokawa, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, Yataro Daigo	107
19	The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer 2006 ·Cancer Research ·Koji Takahashi, Chiyuki Furukawa, Atsushi Takano, Nobuhisa Ishikawa, Tatsuya Kato, Satoshi Hayama, Chie Suzuki, Wataru Yasui, Kouki Inai, Saburo Sone, Tomoo Ito, Hitoshi Nishimura, Eiju Tsuchiya, Yusuke Nakamura, Yataro Daigo	112
20	Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer 2005 ·Cancer Research ·Chiyuki Furukawa, Yataro Daigo, Nobuhisa Ishikawa, Tatsuya Kato, Tomoo Ito, Eiju Tsuchiya, Saburo Sone, Yusuke Nakamura	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact